Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
2018; Massachusetts Medical Society; Volume: 378; Issue: 9 Linguagem: Inglês
10.1056/nejmoa1705716
ISSN1533-4406
AutoresDjillali Annane, Alain Renault, Christian Brun‐Buisson, Bruno Mégarbane, Jean‐Pierre Quenot, Shidasp Siami, Alain Cariou, Xavier Forceville, Carole Schwebel, Claude Martin, Jean‐François Timsit, Benoît Misset, Mohamed Ali Benali, Gwenhaël Colin, Bertrand Souweine, Karim Asehnoune, Emmanuelle Mercier, Loïc Chimot, Claire Charpentier, Bruno François, Thierry Boulain, Franck Petitpas, Jean‐Michel Constantin, Gilles Dhonneur, François Baudin, Alain Combes, Julien Bohé, Jean-François Loriferne, Roland Amathieu, Fabrice Cook, Michel Slama, O. Leroy, Gilles Capellier, Auguste Dargent, Tarik Hissem, Virginie Maxime, Éric Bellissant,
Tópico(s)Intensive Care Unit Cognitive Disorders
ResumoSeptic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock.
Referência(s)